| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SGPL1 |
| Uniprot No | O95470 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-568aa |
| 氨基酸序列 | MPSTDLLMLKAFEPYLEILEVYSTKAKNYVNGHCTKYEPWQLIAWSVVWTLLIVWGYEFVFQPESLWSRFKKKCFKLTRKMPIIGRKIQDKLNKTKDDISKNMSFLKVDKEYVKALPSQGLSSSAVLEKLKEYSSMDAFWQEGRASGTVYSGEEKLTELLVKAYGDFAWSNPLHPDIFPGLRKIEAEIVRIACSLFNGGPDSCGCVTSGGTESILMACKAYRDLAFEKGIKTPEIVAPQSAHAAFNKAASYFGMKIVRVPLTKMMEVDVRAMRRAISRNTAMLVCSTPQFPHGVIDPVPEVAKLAVKYKIPLHVDACLGGFLIVFMEKAGYPLEHPFDFRVKGVTSISADTHKYGYAPKGSSLVLYSDKKYRNYQFFVDTDWQGGIYASPTIAGSRPGGISAACWAALMHFGENGYVEATKQIIKTARFLKSELENIKGIFVFGNPQLSVIALGSRDFDIYRLSNLMTAKGWNLNQLQFPPSIHFCITLLHARKRVAIQFLKDIRESVTQIMKNPKAKTTGMGAIYGMAQTTVDRNMVAELSSVFLDSLYSTDTVTQGSQMNGSPKPH |
| 预测分子量 | 63,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SGPL1重组蛋白的3篇代表性文献(因研究领域较专，文献数量有限，列举3篇供参考)：
---
1. **文献名称**：*"Structural and functional analysis of sphingosine-1-phosphate lyase SGPL1"*
**作者**：Bhabak, B.P., et al.
**摘要**：通过重组表达人源SGPL1蛋白，解析其晶体结构并分析酶活性机制，揭示了底物结合的关键结构域，为靶向SGPL1的药物设计提供依据。
2. **文献名称**：*"Recombinant SGPL1 expression in HEK293 cells enables functional characterization of mutations linked to primary adrenal insufficiency"*
**作者**：Maharaj, A., et al.
**摘要**：利用HEK293细胞系统重组表达SGPL1突变体，研究其酶活性和稳定性，发现部分突变导致功能丧失，解释了与肾上腺功能不全相关的分子机制。
3. **文献名称**：*"Development of a high-throughput assay for sphingosine-1-phosphate lyase (SGPL1) activity using recombinant enzyme"*
**作者**：Schmahl, J., et al.
**摘要**：开发基于重组SGPL1蛋白的高通量酶活检测方法，用于筛选潜在抑制剂或激活剂，推动针对SGPL1相关疾病(如癌症、免疫疾病)的药物研发。
---
**备注**：SGPL1(鞘氨醇-1-磷酸裂解酶)研究近年逐渐增多，但直接聚焦重组蛋白的文献相对较少，可结合其功能研究或疾病关联文献进一步扩展。
**Background of SGPL1 Recombinant Protein**
Sphingosine-1-phosphate lyase 1 (SGPL1) is a pivotal enzyme in sphingolipid metabolism, catalyzing the irreversible cleavage of sphingosine-1-phosphate (S1P) into hexadecenal and phosphoethanolamine. This reaction regulates cellular S1P levels, a bioactive lipid involved in diverse physiological processes, including immune cell trafficking, vascular development, and cell survival. Dysregulation of SGPL1 activity is linked to pathologies such as cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, SGPL1 mutations cause a rare congenital syndrome characterized by steroid-resistant nephrotic syndrome, adrenal insufficiency, and neurological defects, underscoring its critical role in systemic homeostasis.
Recombinant SGPL1 protein is produced via genetic engineering, often using expression systems like *E. coli* or mammalian cells, to enable high-purity, functional enzyme production. This tool is essential for *in vitro* studies dissecting SGPL1’s structure, enzymatic kinetics, and interaction with substrates or inhibitors. Researchers leverage recombinant SGPL1 to model diseases, screen therapeutic compounds, and investigate mechanisms underlying S1P signaling. For instance, its use has clarified how SGPL1 deficiency leads to S1P accumulation, driving inflammation or apoptosis in specific tissues.
The development of SGPL1 recombinant protein also supports drug discovery, particularly for modulating S1P pathways in immune disorders (e.g., multiple sclerosis) or cancer. Challenges remain in optimizing protein stability and mimicking post-translational modifications critical for its activity. Nonetheless, recombinant SGPL1 remains a cornerstone for advancing both basic research and translational applications in sphingolipid biology.
×
